Research Article
A Clinical Model for the Prediction of Acute Exacerbation Risk in Patients with Idiopathic Pulmonary Fibrosis
Table 1
Patient characteristics of the training and test groups.
| | Characteristic | Training group () | Verification group () |
| | AE-IPF | 16 (20.51) | 4 (12.50) | | Demographic and clinical characteristics | | Gender | | | | Male | 48 (61.54) | 18 (56.25) | | Female | 30 (38.46) | 14 (43.75) | | Age | | | | ≤60 | 9 (11.54) | 4 (12.50) | | 61-65 | 11 (14.10) | 2 (6.250) | | >65 | 58 (74.36) | 26 (81.25) | | Occupational | 8 (10.26) | 3 (9.38) | | Smoking | 16 (20.51) | 4 (12.50) | | Comorbidities | | DM | 17 (21.79) | 3 (9.38) | | EH | 7 (8.97) | 6 (18.75) | | CHD | 10 (12.82) | 4 (12.50) | | CI | 11 (14.10) | 5 (15.63) | | GERD | 11 (14.10) | 6 (18.75) | | Hypothyroidism | 4 (5.13) | 1 (3.13) | | OSAHS | 3 (3.85) | 0 | | Lung function | | FVC% predicted | | | | >75 | 16 (20.51) | 4 (12.50) | | 50-75 | 47 (60.26) | 24 (75.00) | | <50 | 15 (19.23) | 4 (12.50) | | DLco% predicted | | | | >55 | 19 (24.36) | 6 (18.75) | | 35-55 | 41 (52.56) | 20 (62.50) | | <35 | 18 (23.08) | 6 (18.75) | | Drug therapy | | Acetylcysteine | 16 (20.51) | 3 (9.38) | | Pirfenidone | 5 (6.41) | 0 | | Glucocorticoid | 12 (15.38) | 4 (12.50) | | Acid-inhibitory drugs | 5 (6.41) | 2 (6.25) |
|
|
Abbreviations: AE-IPF: acute exacerbation of idiopathic pulmonary fibrosis; DM: diabetes mellitus; EH: essential hypertension; CHD: coronary heart disease; CI: cerebral infarction; GERD: gastroesophageal reflux disease; OSAHS: obstructive sleep apnea-hypopnea syndrome; FVC: forced vital capacity; DLCO: diffusion capacity for carbon monoxide; NAC: N-acetylcysteine; PFD: pirfenidone; GC: glucocorticoid.
|
